NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

B-Cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

Antigen-specific T cells CART/CTL and DCvac

Antigen-specific T cells CAR-T/CTL and DCvac cells to treat B-ALL

Trial Locations (1)

RECRUITING

Shenzhen Geno-Immune Medical Institute, Shenzhen

All Listed Sponsors

lead

Shenzhen Geno-Immune Medical Institute

OTHER